.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights

Panelists discuss how the BRAF-KIAA-1549 fusion impacts treatment decisions in cancers like such as low-grade gliomas, emphasizing the role of targeted therapies and the importance of molecular testing for optimal patient disease management.

EP. 1: Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease

December 23rd 2024

Panelists discuss how the treatment approach for relapsed or progressive follicular lymphoma (R/R FL) in the second-line (2L) setting is evolving, focusing on the role of observation vs intervention and the potential impact of ASH 2024 updates, including the inMIND study with tafasitamab and the EPCORE NHL-2 trial with epcoritamab + R2.